Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (Nasdaq: TIVC) generates news that reflects its evolution into a diversified immunotherapeutics and health technology company. This page aggregates coverage of Tivic’s progress in biologics, bioelectronic medicine and contract development and manufacturing, giving investors and observers a single place to review its latest corporate announcements.
Much of Tivic’s recent news flow centers on Entolimod™, its lead Toll-like Receptor 5 (TLR5) agonist drug candidate for acute radiation syndrome (ARS) and related conditions. Articles highlight milestones such as cell line verification, large-scale manufacturing runs, and steps toward current Good Manufacturing Practice (cGMP) production in preparation for a potential Biologics License Application (BLA). Releases also discuss Entolimod’s Fast Track and Orphan Drug designations, its development under the FDA’s Animal Rule, and animal data showing effects on survival, gastrointestinal recovery and hematopoiesis after radiation exposure.
Another major theme in Tivic news is its acquisition of manufacturing and development assets and the launch of Velocity Bioworks™, a wholly owned CDMO subsidiary. Coverage describes how Velocity Bioworks is expected to support Tivic’s own biologics pipeline and offer development and manufacturing services to third-party biotech companies, creating additional revenue opportunities and reducing reliance on external manufacturers.
Visitors will also find updates on Tivic’s bioelectronic program, including results from a clinical optimization trial of non-invasive cervical vagus nerve stimulation conducted with The Feinstein Institutes for Medical Research at Northwell Health. These stories detail how personalized stimulation parameters can influence autonomic measures such as heart rate variability.
In addition, Tivic regularly reports on its interactions with government and industry stakeholders, including BARDA TechWatch meetings, participation in the Military Health System Research Symposium, and conference presentations outlining its strategic transformation. For investors tracking TIVC, this news feed offers a consolidated view of clinical, manufacturing, partnership and capital markets developments.
Tivic Health Systems announced the closing of a $4.0 million public offering. The offering included 4,710,000 shares of common stock, Series A warrants for 4,710,000 shares, and Series B warrants for 7,065,000 shares, all priced at $0.85 per share. The Series A warrants are exercisable immediately and expire in one year, while the Series B warrants also exercisable immediately, expire in five years. Maxim Group served as the sole placement agent. The gross proceeds before fees and expenses amounted to $4.0 million. The offering was made through a registration statement declared effective by the SEC on May 9, 2024. Investors can access the final prospectus on the SEC website.
Tivic Health Systems, a health tech company, announced the pricing of a public offering consisting of common stock and warrants, expecting to raise approximately $4.0 million. The offering includes Series A and Series B warrants with different terms and exercise prices. The closing is scheduled for May 13, 2024, subject to customary conditions. Maxim Group is the sole placement agent for the offering.
Tivic Health announced successful completion of a pilot research study showing the effectiveness of their non-invasive vagus nerve stimulation approach in inducing responses in the autonomic, cardiac, and central nervous systems. Results included a 97% increase in heart rate variability and changes in brain activity consistent with reduced arousal and anxiety. The company aims to improve bioelectronic medicine and expand into new market segments. VNS is a growing market with significant potential in various medical conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
